Sweet Vernal Grass Allergy: The Grass That Accidentally Helped Invent Warfarin

The connection is one of the most surprising stories in pharmaceutical history. Sweet vernal grass (Anthoxanthum odoratum) contains coumarin — the aromatic compound responsible for the characteristic sweet smell of freshly mown hay. In the 1920s and 1930s, cattle in the northern United States and Canada began dying from mysterious hemorrhagic disease after consuming poorly dried hay made from sweet-clover grass and, in some cases, sweet vernal-containing hay. The hay had fermented, converting coumarin into dicoumarol — a potent anticoagulant — that caused fatal internal bleeding. Veterinarian Frank Schofield first identified the problem in 1921, and biochemist Karl Paul Link at the University of Wisconsin completed the chemistry decades later, isolating and characterizing dicoumarol. From this work, Link and his team developed warfarin — named after the Wisconsin Alumni Research Foundation (WARF) — initially as a rat poison in 1948, and later as a therapeutic anticoagulant now used in millions of cardiac and stroke-prevention patients worldwide. Sweet vernal grass is not the only coumarin-containing plant, but it is the species most directly associated with the hay fever botanical family from which this pharmaceutical thread originates.

This is a reasonable clinical concern, but normal environmental exposure to sweet vernal grass — including pollen inhalation and incidental contact — does not deliver meaningful doses of coumarin capable of affecting warfarin therapy. The coumarin in sweet vernal grass is primarily concentrated in leaf and stem tissue, not in the pollen, and is not significantly absorbed through inhalation at ambient pollen concentrations. The historical cattle toxicity occurred because livestock consumed large quantities of fermented hay containing high concentrations of dicoumarol — a converted form of coumarin — as their primary food source over extended periods. Patients on warfarin who live in areas with sweet vernal grass and experience normal pollen season exposures do not need to take special precautions related to anticoagulation management. However, patients who intentionally consume sweet vernal grass as a tea, herbal supplement, or in large food quantities should discuss this with their prescribing physician, as high dietary coumarin from any source may theoretically interact with vitamin K-dependent anticoagulation. Standard allergy treatment for sweet vernal grass sensitization — antihistamines, INCS, immunotherapy — does not interact with warfarin therapy.

Largely yes, but with a nuance. Sweet vernal grass is a Pooideae sweet grass like timothy and shares the same Group 1 and Group 5 allergen protein families that drive approximately 95% cross-reactivity across the subfamily. For most patients, a positive Phl p 5 test confirms Pooideae sensitization that includes sweet vernal grass, and timothy-based immunotherapy (Grastek) covers sweet vernal through cross-reactivity. However, one analysis found that sweet vernal grass has a lower antigenic similarity with timothy — approximately 38% — compared to the much higher similarity between ryegrass, orchard, fescue, or bluegrass and timothy. This lower similarity value was part of the scientific rationale for explicitly including sweet vernal in Oralair (the 5-grass SLIT tablet) alongside timothy, rather than relying solely on cross-reactivity. For patients with primary or high-density sweet vernal sensitization who do not respond fully to Grastek, switching to Oralair or custom SLIT drops that include Anthoxanthum extract may provide more complete coverage.

If your seasonal allergy symptoms begin in April — several weeks before the June peak most allergy guides describe — sweet vernal grass and orchard grass are the two most likely culprits. Both are Pooideae grasses that bloom earlier in spring than timothy (which defines the conventional June grass season), with sweet vernal starting as early as late March or April in warmer regions and orchard grass typically peaking in May. Together, these two early-blooming Pooideae species drive the April-May portion of grass pollinosis that standard grass season calendars underemphasize. The practical implication is significant: patients with April grass symptoms should start antihistamines and intranasal steroids in mid-March rather than late May, and skin testing for both sweet vernal and orchard grass — not just timothy — should be included in the evaluation. Immunotherapy for April-symptom grass patients should also be initiated early enough to provide protection before the April sweet vernal window, which means starting treatment by December or January to meet the 12-week pre-season requirement for SLIT tablets.

Sweet vernal grass allergy can trigger oral allergy syndrome (OAS) through proteins structurally similar between grass pollen and certain plant foods. The most common grass-OAS foods include melon (particularly watermelon and cantaloupe), raw tomato, fresh orange juice, peach and other stone fruits, raw celery, and — in some patients with broader cross-reactivity — kiwi. OAS symptoms are typically localized to the mouth and throat: itching, tingling, or mild swelling within minutes of eating the raw food, resolving spontaneously within a few minutes. Cooking or peeling the food usually eliminates OAS because heat denatures the cross-reactive proteins. Serious systemic reactions from grass OAS are uncommon but have been reported; throat tightening or swallowing difficulty should prompt allergy evaluation. Patients bothered by OAS from any of these foods can typically continue eating them safely by choosing cooked or canned forms, or by consuming them outside the April–July sweet vernal pollen season when total IgE burden is lower.

Several signs indicate that self-management with over-the-counter treatments is insufficient and an allergist evaluation is warranted. If your symptoms during the April–July sweet vernal and general grass pollen window are significantly impairing sleep, work performance, or daily activities despite using a second-generation antihistamine and an intranasal corticosteroid correctly, that symptom burden justifies formal evaluation. Similarly, if you are developing symptoms that begin earlier each year, last longer into summer, or now include chest tightness and wheezing in addition to nasal symptoms, an allergist should assess whether asthma has developed. New symptoms in April that are difficult to distinguish from late tree pollen — and that are not responding to your usual tree pollen medications — often indicate early grass sensitization requiring allergy skin testing to clarify. Finally, patients who want to move beyond annual symptom suppression to long-term disease modification through immunotherapy need an allergist to perform sensitization testing, confirm the allergen profile, and prescribe an appropriate SLIT tablet or custom drop regimen. OTC treatments are appropriate for mild, well-controlled seasonal symptoms; moderate to severe impairment or ambiguity about the trigger allergen calls for specialist evaluation.

Adult-onset grass pollen sensitization, including to sweet vernal grass, is well documented and not uncommon. Allergic sensitization requires both genetic susceptibility and cumulative environmental exposure — the immune system can develop new IgE responses at any age under the right conditions. Several scenarios promote adult-onset grass allergy: relocating to a region with higher sweet vernal grass density, spending increased time outdoors (new hobbies, career changes involving outdoor work), immune system shifts associated with pregnancy or other physiological changes, or the natural evolution of atopic disease in susceptible individuals who may have had subclinical sensitization for years before symptoms emerged. Patients who experience new April or spring symptoms in adulthood — particularly if the symptoms respond poorly to antihistamines calibrated for tree pollen — should consider grass skin testing or serum IgE testing that specifically includes sweet vernal grass extract (ImmunoCAP g1) alongside the standard grass panels. Early identification of adult-onset sensitization and early entry into immunotherapy produces substantially better long-term outcomes than waiting until symptoms escalate over multiple seasons before seeking evaluation.

Yes — sweet vernal grass's April onset overlaps substantially with late tree pollen season in most regions. In the Northeast and mid-Atlantic, oak and maple peak from late March through early May, overlapping with sweet vernal grass onset in April. In the Pacific Northwest, birch peaks in April and May, coinciding almost exactly with sweet vernal grass pollen. This overlap makes it genuinely difficult to distinguish tree pollen from grass pollen symptoms by season timing alone. Several clues help differentiate them: tree pollen allergy often produces more prominent eye and throat itching relative to nasal congestion, while grass pollen tends to produce more pronounced nasal congestion, sneezing, and rhinorrhea. Symptoms that persist or worsen after oak and maple season ends in mid-May — when tree counts drop but total allergy burden remains high — suggest that grass pollen has taken over as the primary driver. Allergy skin testing with separate tree and grass panels, including sweet vernal grass extract, is the definitive way to identify which allergens are actually driving April symptoms. This distinction matters for treatment: antihistamines cover both sources equally, but immunotherapy targets are allergen-specific and the timing of initiation differs between tree and early grass programs.